Hosted on MSN3d
EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
The safety results from the EoE KIDS study were consistent with the known safety profile of Dupixent in adolescents and ...
Pharmabiz3d
EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year
EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...
Sanofi’s Dupixent Gains EU Approval for Pediatric Eosinophilic Esophagitis
Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...
Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)
Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...
The Pharma Letter4d
Another Dupixent approval in the EU
French pharma major Sanofi’s Dupixent (dupilumab), which notched up sales of 3.5 billion euros ($3.8 billion) in ...
Daily3d
Sanofi, Regeneron Dupixent approved in EU for young children with eosinophilic esophagitis
Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...
Medical News Today13d
Dupixent interactions: Alcohol, medications, and other factors
Dupixent (dupilumab) is a brand-name subcutaneous injection that’s prescribed for certain inflammatory conditions. Dupixent has interactions with some other drugs. Examples include certain ...
Yahoo Finance4d
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
TARRYTOWN, N.Y. and PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent ...
Yahoo Finance4d
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
Approval based on phase 3 data showing significantly more children aged one to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up ...
Morningstar5d
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to ...